19.12.2016 PASS DiabCancer – Post-authorisation safety study to assess the risk of urinary tract malignancies in relation to empagliflozin exposure in patients with type 2 diabetes: a multi-database European study. Study accepted in the EU PAS Register. More detailed information about the study available here.
23.11.2016 – Our new article on cardiovascular medicine has been published in BMJ Open. Clinical factors associated with initiation of and persistence with ADP receptor-inhibiting oral antiplatelet treatment after acute coronary syndrome: a nationwide cohort study from Finland. Published in BMJ Open 2016;6:e012604. Article
5.10.2016 – EPID Research is growing. We recently renewed and expanded our head office in Espoo. Now we are looking for new talented people to join us. We currently have the following positions open: Director – Real-World Evidence, Pharmacoepidemiologist and Study Coordinator.
1.9.2016 – Ville Kytö presented two posters of a study conducted by EPID Research in ESC Congress 2016, 27-31 August, 2016: – Gender differences in oral antiplatelet treatment use – results from a nationwide cohort study of acute coronary syndrome patients in Finland – Poster – Age predicts initiation of and persistence with P2Y12 inhibitor treatment […]
29.8.2016 – EPID Research presented four posters in ICPE 32nd International Conference, 25-28 August, 2016: – Contraindicated and off-label drug use in pediatric outpatients in the Nordic countries – Spotlight poster – COPD Patients Initiating Roflumilast in Sweden, Germany and the United States: Findings from the Roflumilast PASS study – Poster – The quality of warfarin therapy among atrial […]
16.8.2016 – Our new article on pioglitazone use and risk of bladder cancer in patients with type 2 diabetes has been published in BMJ. Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries. Published in BMJ 2016;354:i3903. Press Release – Article
4.7.2016 – Our recently published article on cardiac mortality and use of progestin for menopause in Journal of Endocrinology & Metabolism has been cited in the Duodecim publication (in Finnish) – Duodecim article
12.5.2016 – Our new article on cardiac mortality and use of progestin for menopause has been published. Cardiac Death Risk in Relation to the Age at Initiation or the Progestin Component of Hormone Therapies. Published in Journal of Endocrinology & Metabolism, doi: 10.1210/jc.2015-4149 – Article
15.4.2016 – EPID Multiple Sclerosis Pregnancy study – Pregnancy outcomes in Multiple Sclerosis populations exposed and unexposed to interferon beta – a register-based study in the Nordic countries. Study accepted in the ENCePP E-Register of studies. More detailed information about the study available here.
31.3.2016 – Our new article on mortality and use of certain basal insulins has been published. All-cause and cause-specific mortality among users of basal insulins NPH, detemir and glargine. Published in PLoS One 2016, doi:10.1371/journal.pone.0151910 –Article